Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Coverage Initiated on 'Solid Platform Company' with Sanofi Partnership
Research Report

Share on Stocktwits


The reasons why this biopharma makes a compelling investment are outlined in a ROTH Capital Partners report.

In a June 18 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on Translate Bio (TBIO:NASDAQ), in advance of an anticipated Q3/19 data readout, with a Buy rating and a $25 per share target price. The company's current share price is about $13.16.

Translate Bio is a Massachusetts-based company that is developing mRNA therapies for cystic fibrosis and ornithine transcarbamylase deficiency.

Butler listed the key attributes of Translate Bio that justify ROTH's Buy rating on it. They are as follows.

1. The company has a solid platform based on a modular manufacturing process for its mRNA and lipid-based nanoparticle delivery vehicle. With it, Translate Bio can make new mRNA therapies and, therefore, easily venture into new indications.

2. The company's lead clinical program, MRT5005 for cystic fibrosis, is in the multiple ascending dose phase of the ongoing Phase 1/2 study. Translate Bio is expected to report interim data from the trial in Q3/19.

3. The company has a beneficial agreement with Sanofi to develop up to five vaccines. The partnership should diversify Translate Bio's pipeline and provide it with revenue. Sanofi already paid a $45 million upfront payment to the company and will pay up to $805 million plus tiered royalties.

4. The company is well funded through year-end 2020, well past the data readout, thanks to its recent raise of $47 million.

Butler explained that ROTH's $25 target price is based on these assumptions: a 45% probability that MRT5005 is successful in adults and a 35% chance of success in 12 to 17 year olds, a 70–85% penetration rate during the fourth or fifth year of commercialization and about $1 billion in risk-adjusted revenues in 2028.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, Translate Bio, Inc., Company Note, June 18, 2019

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of Translate Bio, Inc. and as such, buys and sells from customers on a principal basis.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe